Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 
Search Results



Your search returned 1870 record(s).

Page 10 of 187  |  Previous Page   |  Next Page

Cancer Type:   Sort By:

This Search was Made Possible by:


  Survival: Patients: Toxicity: Treatment: Hospital: Country: Date:
91 35.3 months Advanced Metastatic Breast Cancer 4 Chemotherapy
Peking Union Medical College China 6/2015
Treatment Details: Patients: This phase 3 study involved female advanced metastatic breast cancer patients who were divided into two separate treatment groups. Group A consisted of 104 patients with a median
 
92 35.2 months Recurrent platinum-sensitive ovarian cancer 5 Chemotherapy
Memorial Sloan-Kettering Cancer Center United States 6/2012
Treatment Details: Patients: This phase 3 study involved platinum-sensitive recurrent ovarian, primary peritoneal, or fallopian tube cancer patients who had received prior platinum-based chemotherapy. Patien
 
93 35.2 months Recurrent platinum-sensitive ovarian cancer, primary fallopian tube cancer, primary peritoneal cancer 5 Biologic therapy
Chemotherapy
Memorial Sloan-Kettering Cancer Center United States 6/2012
Treatment Details: Patients: This phase 3 study involved platinum-sensitive recurrent ovarian, primary peritoneal, or fallopian tube cancer patients who had received prior platinum-based chemotherapy. Patien
 
94 35.0 months Recurrent Ovarian Cancer 4 Chemotherapy
Surgery
University of Nice-Sophia Antipolis France 4/2015
Treatment Details: Patients: This study involved 15 elderly recurrent ovarian cancer patients with a median age of 72 years (range: 70-77). Treatment: Patients received surgery and chemotherapy with cispl
 
95 35.0 months GBM 2 Radiation
Research Center for Charged Particle Therapy Japan 10/2007
Treatment Details: Patients: This phase I/II trial involved 48 patients with malignant gliomas. Sixteen patients had anaplastic astrocytoma and 32 had glioblastoma multiforme. The median age was 53 years, r
 
96 35.0 months Metastatic hormone-refractory prostate cancer 5 Immunotherapy
Seattle Cancer Care Alliance United States 9/2008
Treatment Details: Patients: This phase I/II study involved 80 men with metastatic, hormone refractory prostate cancer. Their median age was 69, ranging from 49 to 90 years old. Treatment: Patients were
 
97 34.7 months Metastatic, Castration-Resistant Prostate Cancer 5 Hormone
UCSF Helen Diller Family Comprehensive Cancer Center United States 2/2015
Treatment Details: Patients: This phase 3 study involved chemotherapy-nave metastatic castration-resistant prostate cancer patients who were separated into two treatment groups. Group A consisted of 546 pati
 
98 34.7 months Epithelial ovarian cancer and fallopian tube or primary peritoneal carcinoma 4 Chemotherapy
University Medical Center Groningen Netherlands 6/2012
Treatment Details: Patients: This study involved women with epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas. Patients were divided into two separate treatment groups. Group A cons
 
99 34.6 months Advanced breast cancer 4 Chemotherapy
Regina Elena National Cancer Institute Italy 4/2011
Treatment Details: Patients: This study involved women with advanced breast cancer who had not received prior anthracycline-based therapy. Patients were divided into two separate treatment groups. Group A c
 
100 34.4 months Epithelial ovarian cancer 4 Biologic therapy
Chemotherapy
Evangelisches Krankenhaus Germany 8/2012
Treatment Details: Patients: This study involved women with epithelial ovarian cancer who had had no prior radiotherpy or chemotherapy. Patients were divided into two separate treatment groups. Group A had
 
Page 10 of 187  | Previous Page  | Next Page